Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 7/20 | 1.00 |
| ▸ | PRKDC | P78527 | 9/20 | 0.75 |
| ▸ | MTOR | P42345 | 3/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29614884 | 1.00 | ATM (1.00) | ATMPRKDCMTORPIK3CAPIK3CD | |
| SCHEMBL18114235 | 0.89 | ATM (0.80) | ATMPRKDCMTORPIK3CAPIK3CD | |
| SCHEMBL20031059 | 0.87 | PRKDC (0.77) | ATMPRKDCFGFR1FGFR2FGFR4 | |
| SCHEMBL256590 | 0.87 | ATM (0.78) | ATMPRKDCMTORKCNH2 | |
| SCHEMBL257265 | 0.87 | ATM (0.78) | ATMPRKDCMTORPIK3CAPIK3CD | |
| SCHEMBL257264 | 0.87 | ATM (0.76) | ATMPRKDCMTORPIK3CAPIK3CD | |
| SCHEMBL166632 | 0.87 | ATM (0.76) | ATMPRKDCMTORPIK3CAPIK3CD | |
| SCHEMBL20730886 | 0.86 | ATM (0.76) | ATMPRKDCMTORPIK3CAPIK3CD | |
| SCHEMBL18125273 | 0.86 | ATM (0.76) | ATMPRKDCMTORPIK3CAPIK3CD | |
| SCHEMBL30342459 | 0.86 | ATM (0.76) | ATMPRKDCMTORPIK3CAPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11478459-B2 | Pharmaceutical preparation | MERCK PATENT GMBH (DE) | 2022-10-25 | — | — | US | claimed |
| EP-3664778-B1 | PHARMACEUTICAL PREPARATION COMPRISING 3-FLUORO-4-[7-METHOXY-3-METHYL-8-(1-METHYL-1 H-PYRAZOL-4-YL)-2-OXO-2,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-1-YL]-BENZONITRILE | MERCK PATENT GMBH (DE) | 2022-05-25 | — | — | EP | claimed |
| US-20210353614-A1 | COMPOUNDS AND USES THEREOF TO TREAT TUMORS IN A SUBJECT | MERCK PATENT GMBH (DE) | 2021-11-18 | — | — | US | claimed |
| EP-3765019-A1 | COMPOUNDS AND USES THEREOF TO TREAT TUMORS IN A SUBJECT | Merck Patent GmbH (DE) | 2021-01-20 | — | — | EP | claimed |
| CN-111867589-A | Compounds for treating tumors in a subject and uses thereof | 默克专利股份有限公司 | 2020-10-30 | — | — | CN | claimed |
| US-20200237733-A1 | PHARMACEUTICAL PREPARATION | MERCK PATENT GMBH (DE) | 2020-07-30 | — | — | US | claimed |
| EP-3664778-A1 | PHARMACEUTICAL PREPARATION COMPRISING 3-FLUORO-4-[7-METHOXY-3-METHYL-8-(1-METHYL-1 H-PYRAZOL-4-YL)-2-OXO-2,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-1 -YL]-BENZONITRILE | Merck Patent GmbH (DE) | 2020-06-17 | — | — | EP | claimed |
| WO-2019175243-A1 | COMPOUNDS AND USES THEREOF TO TREAT TUMORS IN A SUBJECT | MERCK PATENT GMBH (DE) | 2019-09-19 | — | — | WO | claimed |
| WO-2019030302-A1 | PHARMACEUTICAL PREPARATION COMPRISING 3-FLUORO-4-[7-METHOXY-3-METHYL-8-(1-METHYL-1 H-PYRAZOL-4-YL)-2-OXO-2,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-1 -YL]-BENZONITRILE | MERCK PATENT GMBH (DE) | 2019-02-14 | — | — | WO | claimed |
| US-20230226041-A1 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | MERCK PATENT GMBH (DE) | 2023-07-20 | — | — | US | disclosed |
| US-20230226041-A1 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | MERCK PATENT GMBH (DE) | 2023-07-20 | — | — | US | disclosed |
| US-20230044248-A1 | COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER | ARES TRADING S.A. (CH) | 2023-02-09 | — | — | US | disclosed |
| US-11478459-B2 | Pharmaceutical preparation | MERCK PATENT GMBH (DE) | 2022-10-25 | — | — | US | disclosed |
| US-11478459-B2 | Pharmaceutical preparation | MERCK PATENT GMBH (DE) | 2022-10-25 | — | — | US | disclosed |
| EP-2609082-B1 | IMIDAZO[4,5-C]QUINOLINES AS DNA-PK INHIBITORS | MERCK PATENT GMBH (DE) | 2015-02-18 | — | — | EP | disclosed |
| EP-2609082-B1 | IMIDAZO[4,5-C]QUINOLINES AS DNA-PK INHIBITORS | MERCK PATENT GMBH (DE) | 2015-02-18 | — | — | EP | disclosed |
| US-20130172337-A1 | Imidazo[4,5-c]quinolines as DNA-PK inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172337-A1 | Imidazo[4,5-c]quinolines as DNA-PK inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172337-A1 | Imidazo[4,5-c]quinolines as DNA-PK inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-04 | — | — | US | disclosed |
| WO-2012028233-A1 | IMIDAZO[4,5-C]QUINOLINES AS DNA-PK INHIBITORS | MERCK PATENT GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353614-A1 | COMPOUNDS AND USES THEREOF TO TREAT TUMORS IN A SUBJECT | CD274, PDCD1, PDCD1LG2 | ATM 456/4885PRKDC 2134/4885MTOR 195/4885 |
| US-20230226041-A1 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | ATM, MAVS, SARS1 | ATM 1/4885PRKDC 3193/4885MTOR 168/4885 |
| US-11478459-B2 | Pharmaceutical preparation | CYP3A7, CYP3A4, CYP4B1 | ATM 4632/4885PRKDC 1776/4885MTOR 2463/4885 |
| US-20130172337-A1 | Imidazo[4,5-c]quinolines as DNA-PK inhibitors | CHEK1, CHEK2, TTK | ATM 7/4885PRKDC 170/4885MTOR 285/4885 |
| US-20230044248-A1 | COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER | ATM, PDCD1, CD274 | ATM 1/4885PRKDC 3060/4885MTOR 1175/4885 |
| US-20200237733-A1 | PHARMACEUTICAL PREPARATION | CYP3A7, CYP3A4, CYP4B1 | ATM 4632/4885PRKDC 1776/4885MTOR 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.